<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03758170</url>
  </required_header>
  <id_info>
    <org_study_id>NBF_HK_01_2018</org_study_id>
    <nct_id>NCT03758170</nct_id>
  </id_info>
  <brief_title>High-Dose Steroid for Knee Arthroplasty</brief_title>
  <official_title>High-Dose Steroid for Total Knee Arthroplasty - A Randomized Doubleblinded Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sygehus Lillebaelt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Copenhagen University Hospital, Hvidovre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Study is to test a higher dose of steroids(Dexamethasone) given just prior&#xD;
      to surgery in the setting of Fast-Track Kneesurgery with Arthroplasty and the effect on&#xD;
      postoperative pain and postoperative inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares a new High-Dose dosage of steroids in the treatment of postoperative pain&#xD;
      after Knee Arthroplasty in a Fast-Track setting.&#xD;
&#xD;
      The investigators compare the already used dose(medium dose) with a new high dose(HD) steroid&#xD;
      given as an intravenous bolus after the spinal anaesthesia has been given, but before the&#xD;
      surgery starts.&#xD;
&#xD;
      The hypothesis is that by attenuating the inflammatory response to the surgery itself by the&#xD;
      steroid Dexamethasone, the investigators expect a reduction in postoperative pain upon&#xD;
      ambulation 24 hours after unilateral Knee Arthroplasty.&#xD;
&#xD;
      Patients referred to Unilateral Total KneeArthroplasty because of knee-osteoarthritis on&#xD;
      Hvidovre Hospital, Capital Region of Denmark or Vejle Hospital, South Region of Denmark are&#xD;
      screened and offered inclusion in the study.&#xD;
&#xD;
      The two groups will be randomized and doubleblinded. One group will be treated, as the&#xD;
      current guideline in the investigator's Orthopedic fast-track Arthroplasty center, with the&#xD;
      medium dose of steroid (0,3 mg dexamethasone/kg bodyweight).&#xD;
&#xD;
      The other group wil be treated with a high dose of steroid (1,0 mg dexamethasone/kg&#xD;
      bodyweight).&#xD;
&#xD;
      The patients will be monitored the first 7 days after surgery, during the admission to the&#xD;
      hospital, and by a Pain-diary in the patients own home.&#xD;
&#xD;
      Blood tests will be taken preoperatively and postoperatively to determine the effect of the&#xD;
      highdose steroid on the inflammatory response. Also a series of blood tests determining the&#xD;
      glucose-metabolism after the steroid-admission.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized doubleblinded controlled trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All intervention drugs will be blinded by a nurse who is not a participant in the study or in the treatment of the patient in any way.&#xD;
The Patient, the administrator of the drug(nurse or doctor), the assessor, the investigator and the care team will all be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain after 24 hours: VAS</measure>
    <time_frame>24 hours</time_frame>
    <description>The amount of patients with moderate postoperative pain in a 5 meter walk test 24 hours postoperatively after total knee-arthroplasty.&#xD;
Pain is monitored by the Visual Analog Scale(VAS) 0-100 mm, where 0 is no pain and 100 mm is the worst pain. Moderate pain is considered a VAS &gt;30 mm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative opioid usage</measure>
    <time_frame>7 days</time_frame>
    <description>The amount of rescue opioids given in the postoperative period, and until 7 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative antiemetics usage</measure>
    <time_frame>7 days</time_frame>
    <description>The amount of rescue antiemetics given in the postoperative period, and until 7 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The inflammatory response expressed by C-reactive protein(CRP).</measure>
    <time_frame>2 days</time_frame>
    <description>The inflammatory response is monitored by the blood-sample c-reactive protein(CRP) and analyzed to se the possible attenuation of the response because of dexamethasone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain summed in the first 7 days</measure>
    <time_frame>7 days</time_frame>
    <description>Pain summarized over the first 7 days after surgery, assessed by a summation of the Visual Analog Scale(VAS)-scores in the first 7 days as noted in the pain diary filed in by the participants.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Why still in hospital, an audit into the reasons the patient has not yet been discharged from the ward.</measure>
    <time_frame>7 days.</time_frame>
    <description>An investigation into reason of why our patients remain in the hospital in the days after total Knee Arthroplasty in our Fast-Track center. This is investigated through a questionnaire previously used in a similar investigation in our center.&#xD;
The questionnaire is filled in by our project nurse. the questionnaire is a checkmark schedule with predetermined reasons to stay in hospital like low bloodpressure, sedation, dizzyness, lack of physiotherapy and medical and surgical complications.&#xD;
The outcome assesment will be descriptive.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <condition>Knee Osteoarthritis</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>High dose Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>An intravenous bolus dose of dexamethasone given prior to surgery.</description>
    <arm_group_label>High dose Dexamethasone</arm_group_label>
    <arm_group_label>Medium dose Dexamethasone</arm_group_label>
    <other_name>Dexa-ratiopharm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 40 and 90.&#xD;
&#xD;
          -  Booked for unilateral knee-arthroplasty.&#xD;
&#xD;
          -  Is able to take part in the investigation(selfreported pain and nausea/vomiting)&#xD;
&#xD;
          -  Understands Danish or English, or has a translator available.&#xD;
&#xD;
          -  Signed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insulin-dependent diabetes melitus.&#xD;
&#xD;
          -  Ongoing treatment with systemic glucocorticoids or immunosuppressing treatment(apart&#xD;
             from inhaled glucocorticoids).&#xD;
&#xD;
          -  Pregnancy/Breastfeeding&#xD;
&#xD;
          -  Allergies for the investigational drug.&#xD;
&#xD;
          -  Daily use of opioids.&#xD;
&#xD;
          -  A pain catastrophizing scale(PCS) score of &gt;20.&#xD;
&#xD;
          -  A history of schizophrenia or bipolar diseases, or patients with permanent use of&#xD;
             antipsychotic medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolai Bang Foss, Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Anaesthesia, Hvidovre Hospital, Capital Region of Denmark.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niklas Ingemann Nielsen, MD</last_name>
    <phone>0045 28 29 34 88</phone>
    <email>Niklas.Ingemann.Nielsen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolai Bang Foss, Dr.Med.</last_name>
    <email>Nicolai.Bang.Foss@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hvidovre Hospital, Capital Region of Denmark.</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Ingemann Nielsen, MD.</last_name>
      <phone>0045 28 29 34 88</phone>
      <email>Niklas.Ingemann.Nielsen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Henrik Husted, MD., Dr.Med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Varnum, MD.</last_name>
      <email>Claus.Varnum@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Claus Varnum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per Kjærsgaard-Andersen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital, Hvidovre</investigator_affiliation>
    <investigator_full_name>Niklas Ingemann Nielsen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Knee Arthroplasty</keyword>
  <keyword>Knee Replacement</keyword>
  <keyword>Perioperative Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available upon reasonable request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>From 1 year after last included patient, and onto 4 years after end of trial.</ipd_time_frame>
    <ipd_access_criteria>Upon reasonable request to the corresponding author</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

